ALPPS versus two stage hepatectomy in colorectal liver metastases

ALPPS versus two stage hepatectomy in colorectal liver metastases - ALPPS vs. TSH in CRLM

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00019002

Enrollment

Registered

2019-11-04

Start date

2019-10-27

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C78.7 C18 C19 C20

Interventions

Group 1: ALPPS (Surveillance from surgery to follow-up) Group 2: TSH/PVE (Surveillance from surgery to follow-up)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients undergoing either ALPPS or TSH/PVE for colorectal liver metastases

Exclusion criteria

Exclusion criteria: Intraoperativ change in strategy

Design outcomes

Primary

Measure	Time frame
Overall survival after surgery	—

Secondary

Measure	Time frame
Recurrence-free survival after surgery; perioperative morbidity and mortality	—

Countries

Germany

Contacts

Public ContactJan Bednarsch

Universitätsklinikum der RWTH Aachen

jbednarsch@ukaachen.de02418089501

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026